Ibogaine & alcohol use disorder
Short answers to common questions about ibogaine, alcohol use disorder, early research, and what remains uncertain.
Plain language
careful uncertainty
no treatment endorsement
This page separates plausible questions from established answers. For broader context, the Open Field 66 research starting point maps the same topic without treating early signals as settled care, while the site’s independence and scope explains the standards behind these summaries.
01 / Core questions
These answers are intentionally brief: they identify what has been studied, where uncertainty remains, and why safety cannot be separated from efficacy.
There is not enough high-quality clinical evidence to establish ibogaine as a treatment for alcohol use disorder. Early observations and individual reports may generate hypotheses, but they do not show that an intervention is effective, appropriate, or safe for a particular person. The question of whether ibogaine treatment works needs to be answered through well-designed studies, not testimonials.
The direct evidence base for alcohol use disorder is limited, and study quality matters as much as study count. Controlled designs, independent replication, meaningful follow-up, transparent adverse-event reporting, and comparison groups all affect how much confidence a result deserves. The National Institute on Alcohol Abuse and Alcoholism overview of alcohol use disorder provides useful context for why a complex condition should not be reduced to a single intervention claim.
Noribogaine is a metabolite formed after ibogaine is processed in the body. It is pharmacologically distinct from ibogaine, but a mechanistic difference is not proof of clinical benefit or safety for alcohol use disorder. Accounts of reported ibogaine aftereffects should be read separately from evidence about noribogaine itself.
No. Findings from opioid-related research cannot simply be transferred to alcohol use disorder because the conditions, evidence base, treatment context, and clinical risks differ. Understanding common names used for ibogaine may help a reader recognize discussion of the substance, but it does not make evidence from one condition interchangeable with another.
ClinicalTrials.gov is a primary registry for checking whether a study is recruiting, active, completed, or published. A listing can clarify a study’s stated aim and eligibility, but registration alone does not establish that a treatment works or is safe. Reported interest in lower-cost ibogaine treatment is a separate access question, not evidence of effectiveness.
02 / Interpreting claims
Claims about addiction treatment are strongest when they identify the population studied, the outcomes measured, the length of follow-up, and the harms observed. A promising result can still be preliminary, and a biological explanation can still fall short of a clinical outcome.
The general reference entry on ibogaine can orient readers to the compound’s background, but primary studies and trial records are more useful for judging a specific alcohol-related claim. Questions about potential mood effects also need their own evidence base; ibogaine and depression-focused claims do not answer the alcohol-use question.
A research question can be worthwhile without becoming a recommendation.
03 / Safety stays central
Any discussion of possible benefit is incomplete without the limits of the evidence, medical screening concerns, and the regulatory setting.
In the United States, ibogaine is listed as a Schedule I controlled substance; the Drug Enforcement Administration’s scheduling information explains the federal scheduling framework. That status is not a clinical verdict, but it is relevant context for interpreting access and research claims.
Potential cardiovascular and other adverse effects are part of the evidence question, not an afterthought. A summary of claimed ibogaine therapy benefits should therefore be weighed against safety reporting, exclusions, and the limits of the underlying research.
A person may encounter overlapping claims about mood and substance use, but each needs condition-specific evidence. Material about ibogaine and depression may raise related questions without establishing an answer for alcohol use disorder.
04 / Keep the question precise
For location-specific discussion, material concerning ibogaine treatment in Seattle should be understood as context rather than a substitute for evidence or medical advice. Open Field 66 remains an independent information resource and does not endorse, arrange, or provide treatment.